" class="no-js "lang="en-US"> Mary Irvine - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mary Irvine

Mary Irvine

About Mary Irvine

Public health professional currently directing a unit of 14 masters- and doctoral-level scientists responsible for program evaluation and intervention research, health services data systems design and documentation, grant writing, project management, performance measurement, and reporting to diverse stakeholders.

Related Story

Diseases

 CUNY SPH and NYC Health Department Awarded $3.3 Million to Study New HIV Intervention | Pharmtech Focus

CUNY SPH and NYC Health Department Awarded $3.3 Million to Study New HIV Intervention

August 19 2021

The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public […]